AbbVie tries a new approach in 340B programme battle
Pharmaphorum
AbbVie has opened a new front in the pharma industry’s efforts to reform the 340B drug discounting programme for safety net hospitals in the US.
The FTC Blows Up Express Scripts’ PBM Model–and Launches the Net Pricing Drug Channel (rerun)
Drug Channels
This week, I’m rerunning some popular posts while we prepare for tomorrow’s live video webinar: PBM Industry Update 2026: Trends, Challenges, and What’s Ahead .
23andMe study explains variable results with obesity drugs
Pharmaphorum
Gene variants could explain why some people lose more weight than others with GLP-1 drugs, and why some are more prone to side effects.
EverSea Medicines to acquire Hasten Biopharmaceuticals
Pharmaceutical Business Review
The acquisition aims to enhance Everest Medicines’ presence and commercial capabilities across key regional markets.
Jeito Capital secures over $1.2bn for new biopharma investments
Pharmaceutical Business Review
The milestone increases Jeito’s assets under management to 1.6bn, following the 534m closure of Jeito I in 2021.
FDA seeks permanent future for rare pediatric priority review vouchers
Pharmaceutical Technology
The rare disease framework has had a turbulent past few years, with the FDA looking to create regulatory stability.
Syneron raises $150m for macrocyclics, and other financings
Pharmaphorum
Our round-up of recent biotech venture capital financings includes nine-figure rounds for Syneron, Stipple Bio, and Sidewinder.
Shionogi secures $482m BARDA contract to tackle AMR crisis
Pharmaceutical Technology
Shionogi will use the money from BARDA to build an American antibiotic manufacturing site as the US looks to fight antimicrobial resistance.
Sidewinder secures $137M to advance ‘precision’ ADCs
BioPharma Dive
Backed by OrbiMed, Novartis venture arm and many other investors, the biotech is among those working on newer technology that could broaden the reach of antibody-drug conjugates.
With 3 quick buyouts, Gilead leans into its latest transformation
BioPharma Dive
On a conference call with analysts, Gilead walked through how a string of recent deals focused on cancer and autoimmune conditions could help a diversification plan it s long struggled to execute.
Gilead Less M&A Happy Now but Door Still Open for ‘Compelling’ Opportunities
BioSpace
Gilead Sciences has inked three deals this year so far totaling $14.77 billion, a marked escalation of the company’s usual M A pace.
Medicare Advantage Insurers Will See Higher Payments as CMS Backs Off a Key Payment Update
KFF Medicare
The Trump administration this week backed off a key element of its Medicare Advantage rate proposal, resulting in billions of dollars in additional payments to private insurers.
Sidewinder pockets $137m in Series B to take bispecific ADCs to clinic
Pharmaceutical Technology
The funding round, led by Novartis and OrbiMed, will allow Sidewinder to progress its bispecific ADC programmes to the clinic.
Activist investor renews its criticism of Novavax
Pharmaphorum
Shah Capital has fired another broadside at vaccine firm Novavax, accusing its board and management of a “destruction in shareholder value.”
Insmed Scraps Skin Plans for Lung Disease Drug as Competitors Make Headway
BioSpace
After a Phase 2 flop, Brinsupri exits the race to market for the chronic skin disease hidradenitis suppurativa, but other companies, including Incyte, Novartis and UCB, have recently notched clinical
Merck Chopped $1B Off Terns’ Offer After Seeing Updated Leukemia Data
BioSpace
Another bidder, which remains unidentified, dropped out of the bidding process.
List Price Reductions Will Deflate the Gross-to-Net Bubble-and Threaten Pharmacy and 340B Profits from IRA-Negotiated Drugs (rerun)
Drug Channels
This week, I’m rerunning some popular posts while we prepare for Friday’s live video webinar: PBM Industry Update 2026: Trends, Challenges, and What’s Ahead .
EU invests 30m to fight antimicrobial resistance
Pharmaphorum
The EU has pledged 30m in funding for countermeasures to antimicrobial resistance, earmarked for the discovery and development of new antibacterials.
RoosterBio and MineBio team up to expand MSC solutions access in China
Pharmaceutical Business Review
MineBio will supply RoosterBio’s complete platform of products, having already obtained import clearance.
Halozyme and Vertex sign deal for Hypercon technology
Pharmaceutical Business Review
Vertex has licensed the technology for use in up to three drug targets, as part of the agreement.